Ionis Pharmaceuticals (MEX:IONS) Total Operating Expense : MXN23,427 Mil (TTM As of Mar. 2025)

View and export this data going back to 2019. Start your Free Trial

What is Ionis Pharmaceuticals Total Operating Expense?

Ionis Pharmaceuticals's Total Operating Expense for the three months ended in Mar. 2025 was MXN5,668 Mil. Ionis Pharmaceuticals's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2025 was MXN23,427 Mil.

Ionis Pharmaceuticals Total Operating Expense Historical Data

The historical data trend for Ionis Pharmaceuticals's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ionis Pharmaceuticals Total Operating Expense Chart

Ionis Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Operating Expense

Get a 7-Day Free Trial

17,251.87

16,705.64

19,173.19

19,218.67

24,380.94

Ionis Pharmaceuticals Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Operating Expense	Get a 7-Day Free Trial															4,428.13	5,261.11	5,540.08	6,957.25	5,668.13

Ionis Pharmaceuticals Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.

Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN23,427 Mil.

Ionis Pharmaceuticals Total Operating Expense Related Terms

Thank you for viewing the detailed overview of Ionis Pharmaceuticals's Total Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Ionis Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ionis Pharmaceuticals Inc (MEX:IONS) » Definitions » Total Operating Expense

Comparable Companies

Traded in Other Exchanges

IONS:USA 0JDI:UK ISI:Germany

Address

2855 Gazelle Court, Carlsbad, CA, USA, 92010

Website

https://www.ionis.com

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.